Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D- peptidoglycan

Medical Oncology

Volumn 15, Issue 1, 1998, Pages 37-43

  Slesarev, Vladimir I ^a,b   Ellithorpe, Rita ^a   Dimitroff, Todor ^a  

^a Institute of Infectious Gynecology   (United States)

^b Institute of Infectious Gynecology Inc   (United States)

Author keywords

GGTP; LDH; N acetyl glucosaminyl muramyldipeptide (GMDP); TNF ; Tumor shock

Indexed keywords

CHOLESTEROL; LACTATE DEHYDROGENASE ISOENZYME; MURAMYL DIPEPTIDE DERIVATIVE; N ACETYLGLUCOSAMINYLMURAMYL DIPEPTIDE; PEPTIDOGLYCAN; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LACTOBACILLUS; LIPID METABOLISM; LUNG CARCINOMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031836597     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787343     Document Type: Article

References (25)

1. Carswell EA, Old LJ, Kassel RL, Williamson B. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci 1875; 72: 3666-3670.
2. Goldhaber JI et al. Effect of TNF-alpha on [Ca2+] and contractivity in isolated adult rabbit ventricular myocytes. Am J Physiol 1996; 271: H1449-H1455.
3. Heinig J et al. Semiquantitative determination of IL-1 alpha, TNF-alpha, PDGF-A, PDGF-B, and PDGF-receptor in term human placenta using polymerase chain reaction (PCR). Gynecol 1993; 115: 317-322.
4. Recdal O, Osterud B, Svendsen JS, Winberg JO. Evidence for exclusive role of the p55 tumor necrosis factor (TNF) receptor in mediating the TNF-induced collagenase expression by human dermal fibroblasts. J Invest Dermatol 1996; 96: 243-249.
5. Owens MW, Grimes SR. Pleural mesothelial cell response to inflammation: tumor necrosis factor induced mitogenesis and collagen synthesis. Am J Physiol 1993; 265: L382-L388.
6. Sakayama K et al. Recombinant human tumour necrosis factor-alpha suppresses synthesis, activity and secretion of lipoprotein lipase in cultures of human osteosarcoma cell line. Biochem J 1996; 316: 813-817.
7. Vassalli P. The Pathophysiology of tumor necrosis factors. Annu Rev Immonol 1992; 10: 411-452.
8. Tracey KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
9. Levine B, Kalman J, Mayer L, Fillit HM. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 223: 236-241.
10. Smith SC, Allen PM. Neutrolization of endogenous tumor necrosis factor amiliorates the severity of myosin induced myocarditis. Circ Res 1992; 70: 856-863.
11. Imagawa DK et al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation 1993; 50: 189-193.
12. Jacobs CA, Smith CA. Methods of lowering active TNF-alpha levels in mammals using tumor necrosis factor I receptor. US patent 5605690 1997.
13. Seckinger PL, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor a. J Exp Med 1988; 167: 1511-1516.
14. Seckinger PL, Zhang JH, Hauptmann B, Dayer JM. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF-receptor. Proc Natl Acad Sci 1990; 87: 5188-5192.
15. Krueger JM, Pappenhaimer JR, Karnovsky ML. Sleep promoting effects of muramyl peptides. J Biol Chem 1982; 257: 1664-1669.
16. Vermeulen MV, David JR, Remold HL. Differential mRNA responses in human macrophages activated by Interferon-y and muramyl peptides. J Immunol 1987; 139: 7-9.
17. Slesarev VL, Efimov VA, Oraevsky AV, Slesarev AI. Nonspecific vaccination by D-aminoacid containing compounds: International patent application WO 08/510,737, 1997.
18. Slesarev VI. US patent application 08/757,477, 1996.
19. Ovchinnikov Yu et al. Glycopeptides and methods for preparing same. US patent 4,395,399, 1983.
20. Andronova T, Ivanov V. The structure and immunomodulating function of glucosaminylmuramyl peptides. Sov Med Rev Immunol 1989; 4: 1-63.
21. Adeleye TA, Moreno C, Ivanyi J, Aston R. The modulation of tumor necrosis factor-a, interleukin-1a and glucose levels with GMDP and other analogues of muramyl dipeptide. APMS 1994; 102: 145-152.
22. Hornung RL, Longo DL, Gowda VL, Kwak LW. Induction of CD8 + cytotoxic lymphocyte response to a soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Ther Immunol 1995; 2: 7-14.
23. Barbara JA, Van Ostade X, Lopez A. Tumor necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Immunol Cell Biol 1996; 74: 434-443.
24. Aston R. Muramyl compounds for treatment of septic shock. US patent 5506204, 1996.
25. Preketes AP et al. Immunological activity and serum CEA levels following oral administration of muramyl dipeptide (GMDP) to patients with advanced colorectal cancer. Surg Res Comm 1996; 18: 137-146.